Free Trial

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb logo
$44.25 +0.94 (+2.17%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$44.32 +0.08 (+0.17%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
13
Buy
7

Based on 21 Wall Street analysts who have issued ratings for Bristol Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 1 has given a sell rating, 13 have given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for BMY.

Consensus Price Target

$57.33
29.57% Upside
According to the 21 analysts' twelve-month price targets for Bristol Myers Squibb, the average price target is $57.33. The highest price target for BMY is $73.00, while the lowest price target for BMY is $34.00. The average price target represents a forecasted upside of 29.57% from the current price of $44.25.
Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol Myers Squibb and its competitors.

Sign Up

BMY Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
13 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$57.33$58.00$58.00$55.79
Forecasted Upside29.57% Upside23.36% Upside14.72% Upside14.36% Upside
Consensus Rating
Hold
Hold
Hold
Hold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bristol Myers Squibb Stock vs. The Competition

TypeBristol Myers SquibbMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside29.57% Upside10,407.36% Upside14.55% Upside
News Sentiment Rating
Positive News

See Recent BMY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/1/2025Citigroup
3 of 5 stars
Andrew Baum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$51.00 ➝ $47.00+6.21%
7/31/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/25/2025Argus
4 of 5 stars
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
4/23/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$70.00 ➝ $68.00+36.49%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00+12.36%
4/22/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00+32.79%
4/11/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$60.00 ➝ $54.00+8.43%
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$67.00 ➝ $55.00+1.97%
2/7/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00+8.37%
1/8/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$62.00 ➝ $65.00+13.60%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$63.00+7.25%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoveragePeer Perform
11/13/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/13/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
11/12/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$57.00 ➝ $61.00+2.09%
11/12/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$55.00 ➝ $73.00+22.03%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$56.00+4.93%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderweight ➝ Underweight$42.00 ➝ $43.00-20.25%
10/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$53.00 ➝ $59.00+9.32%
7/23/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$53.00 ➝ $45.00+5.36%
3/11/2024Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/6/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$77.00 ➝ $54.00+12.50%
10/27/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$55.00 ➝ $53.00+0.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:25 PM ET.


Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 31, 2025. Please send any questions or comments about these Bristol Myers Squibb pros and cons to contact@marketbeat.com.

Bristol Myers Squibb
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

  • The current stock price is around $47.63, which is relatively stable compared to its twelve-month high of $63.33, indicating potential for recovery and growth.
  • Recent quarterly earnings showed a significant earnings per share (EPS) of $1.46, surpassing expectations, which reflects strong financial performance and operational efficiency.
  • The company has a robust product pipeline, including treatments for various cancers and other serious conditions, which could drive future revenue growth.
  • Bristol-Myers Squibb offers a competitive dividend yield of approximately 5.60%, providing a steady income stream for investors.
  • With a market capitalization of around $90.19 billion, Bristol-Myers Squibb is a well-established player in the biopharmaceutical industry, suggesting stability and reliability.

Bristol Myers Squibb
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

  • The company has a high debt-to-equity ratio of 2.65, which may indicate financial risk and could affect its ability to invest in growth opportunities.
  • Despite recent revenue growth, the net margin of 11.38% suggests that profitability could be under pressure, which may concern investors looking for strong returns.
  • Analysts predict a modest EPS of 6.74 for the current fiscal year, which may not meet the expectations of aggressive growth investors.
  • The company’s dividend payout ratio is quite high at 92.88%, which could limit its ability to reinvest in the business or respond to market changes.
  • Recent market volatility and competition in the biopharmaceutical sector could pose challenges to maintaining market share and profitability.

BMY Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol Myers Squibb is $57.33, with a high forecast of $73.00 and a low forecast of $34.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol Myers Squibb in the last twelve months. There is currently 1 sell rating, 13 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.

According to analysts, Bristol Myers Squibb's stock has a predicted upside of 29.57% based on their 12-month stock forecasts.

Bristol Myers Squibb has been rated by research analysts at Citigroup, and Morgan Stanley in the past 90 days.

Analysts like Bristol Myers Squibb less than other "medical" companies. The consensus rating for Bristol Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.


This page (NYSE:BMY) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners